The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,653.00
Bid: 1,654.00
Ask: 1,654.50
Change: 12.50 (0.76%)
Spread: 0.50 (0.03%)
Open: 1,638.50
High: 1,655.50
Low: 1,634.00
Prev. Close: 1,640.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Bank rules force staff to turn off NHS COVID-19 tracing app at work

Thu, 08th Oct 2020 13:32

* Thousands of staff seen at risk of undetected infection -
union

* Some banks ask staff to store phones away to prevent data
leaks

* Govt advises NHS app should be paused if phone not on
person
(Adds Department of Health comment)

By Iain Withers and Sinead Cruise

LONDON, Oct 8 (Reuters) - Branch staff at some of Britain's
biggest banks say rules that require them to store phones in
lockers while at work are putting them at undue risk of COVID-19
from colleagues and customers, as they cannot use the country's
tracing app.

Lloyds Banking Group, along with rival TSB, are
among those advising employees to deactivate the NHS Track &
Trace app during office hours, when they are not allowed to keep
phones on their person.

Some banks ask staff and cashiers to store phones away to
prevent leaks of sensitive customer data, although this is not
formally required by regulator the Financial Conduct Authority.

Under current government guidelines, users of the NHS app
are advised to disable bluetooth or pause the app when away from
their phones to avoid false notifications.

Other companies have told staff to pause the app at work,
including pharmaceuticals firm GSK, which said its other
safety measures were sufficient, the Guardian newspaper
reported.

The BTU union, which represents staff working for Lloyds but
is not recognised by the bank, said it had been contacted by
dozens of staff unable to use the app, which has been downloaded
by more than 14 million people.

One unnamed Lloyds employee who contacted the BTU said: "I
live and work in a high-risk area so I am very concerned at
being told that while I'm at work I have to suspend the NHS test
and trace app... This defeats the object of track and trace."

Another said they were at risk as they had to conduct
face-to-face meetings and due to the "blatant transgression of
the social distancing rules by many customers".

"Customers and staff have a right to know if they have come
into contact with someone who's been infected," said Mark Brown,
general secretary of the BTU.

Although several European countries have launched
Bluetooth-based apps to alert those at risk of catching
COVID-19, there is little evidence to date that the technology
has significantly curbed infections.

Both Lloyds and TSB have advised staff to pause the app's
tracing function while at work, according to internal guidance
issued by each lender seen by Reuters.

"Colleagues who have downloaded the app to their own smart
phone should not use the app while you are at work," Lloyds told
staff, adding it was to stop people receiving false alerts.

A NatWest spokesman said the bank encouraged staff to use
the app but said they should pause it when they are not with
their phone. The bank discourages - though doesn't ban - the use
of personal phones in branches and contact centres.

A spokesman for Barclays said the bank had not advised staff
to turn off the app.

A Department of Health and Social Care spokeswoman said: "We
want as many people to download and use the app as possible. It
is important to use the NHS Covid-19 app at all times, including
while at work, unless in specific scenarios which are clearly
set out in our guidance."

TSB was not immediately available for comment. Lloyds
declined to comment.

A second employee union, Accord, said rules prohibiting use
of personal phones in the workplace were in place to protect
employees from security risks.

"If customers care about the health and well-being of the
bank staff they rely on, they could help by wearing face
coverings when visiting bank branches," Accord's General
Secretary Ged Nichols said.
(Reporting by Iain Withers and Sinead Cruise; Additional
reporting by Douglas Busvine in Berlin; Editing by Rachel
Armstrong, Jan Harvey and Toby Chopra)

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.